OPTIMIZING OUTCOMES IN NONALCHOHOLIC STEATOHEPATITIS (NASH) AND LIVER DISEASES

Uncertainty and risk are inherent to the world of clinical research. Worldwide uses the latest hepatic imaging, diagnostic technology, and analytic techniques to maximize convenience and minimize risk—for patients and sponsors.

FOCUSED EXPERTISE FOR YOUR LIVER DISEASE PROGRAMS

As the rate of liver disease continues to rise, so does the challenge of finding the right patients for clinical trials. Non-alcoholic steatohepatitis (NASH) has few detectable symptoms in its early stages, leading to progressive and more serious disease stages, including cirrhosis, liver failure, liver cancer, and cardiovascular events. To get your investigative medicinal product all the way to market faster to help patients sooner, partner with our experienced team at Worldwide Clinical Trials.

SCOTT BEASLEY

EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, NASH

Scott’s experience includes project management, clinical team management, portfolio development, and training across all phases of development, including compassionate use programs. He has more than 24 years of experience in the industry, with extensive NASH/NAFLD experience in Phase II and several Phase III programs. His proven leadership and strategic protocol and operational expertise ensure successful implementation and delivery for his projects.

RAFAL ZIECINA, MD, PHD

EXECUTIVE DIRECTOR, SCIENTIFIC SOLUTIONS, CARDIOVASCULAR, ENDOCRINE & METABOLIC

With more than 22 years of experience in the World of pharmaceuticals and research, Dr. Ziecina serves as an NAFLD/NASH scientific advisor focused on filing strategies, regulatory and safety strategies. He excels in writing protocols and drug development plans and has extensive experience in study design and medical monitoring for clinical programs.

  • expert image
  • expert image

Strong teams with expertise in liver diseases

You require a true partner that knows the complexities of liver disease trials and has the global expertise to get your product to market. Our award-winning approach combines patient centricity with strong investigative collaboration to arrive at optimal strategies for achieving reliable data on time and within budget.

Liver Disease Experience

  • Acute Liver Failure
  • Alcoholic Hepatitis
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Non-Alcoholic Steatohepatitis (NASH)
  • Primary Sclerosing Cholangitis

Our Dedicated Team